Research ArticleNeuropharmacology
The phosphodiesterase 2A inhibitor TAK-915 ameliorates cognitive impairments and social withdrawal in N-methyl-D-aspartate receptor antagonist-induced rat models of schizophrenia
Masato Nakashima, Haruka Imada, Eri Shiraishi, Yuki Ito, Noriko Suzuki, Maki Miyamoto, Takahiko Taniguchi and Hiroki Iwashita
Journal of Pharmacology and Experimental Therapeutics February 13, 2018, jpet.117.245506; DOI: https://doi.org/10.1124/jpet.117.245506
Masato Nakashima
Takeda Pharmaceutical Company Limited
Haruka Imada
Takeda Pharmaceutical Company Limited
Eri Shiraishi
Takeda Pharmaceutical Company Limited
Yuki Ito
Takeda Pharmaceutical Company Limited
Noriko Suzuki
Takeda Pharmaceutical Company Limited
Maki Miyamoto
Takeda Pharmaceutical Company Limited
Takahiko Taniguchi
Takeda Pharmaceutical Company Limited
Hiroki Iwashita
Takeda Pharmaceutical Company Limited
Jump to comment:
No eLetters have been published for this article.
In this issue
Research ArticleNeuropharmacology
The phosphodiesterase 2A inhibitor TAK-915 ameliorates cognitive impairments and social withdrawal in N-methyl-D-aspartate receptor antagonist-induced rat models of schizophrenia
Masato Nakashima, Haruka Imada, Eri Shiraishi, Yuki Ito, Noriko Suzuki, Maki Miyamoto, Takahiko Taniguchi and Hiroki Iwashita
Journal of Pharmacology and Experimental Therapeutics February 13, 2018, jpet.117.245506; DOI: https://doi.org/10.1124/jpet.117.245506
Research ArticleNeuropharmacology
The phosphodiesterase 2A inhibitor TAK-915 ameliorates cognitive impairments and social withdrawal in N-methyl-D-aspartate receptor antagonist-induced rat models of schizophrenia
Masato Nakashima, Haruka Imada, Eri Shiraishi, Yuki Ito, Noriko Suzuki, Maki Miyamoto, Takahiko Taniguchi and Hiroki Iwashita
Journal of Pharmacology and Experimental Therapeutics February 13, 2018, jpet.117.245506; DOI: https://doi.org/10.1124/jpet.117.245506
Jump to section
Related Articles
Cited By...
More in this TOC Section
Similar Articles
Advertisement